The model can manage missing or uncertain data and includes patient-specific clinical, histological, and genetic information, such as tumor type, stage, and PD-L1 expression.<h4>Results</h4>Using data from 66 patients with either basal cell carcinoma (BCC) or cSCC, we retrospectively validated the model by comparing the treatment recommendations from the tool with the actual choices made by multidisciplinary tumor boards. This evidence concerns the gene CD274 and basal cell carcinoma.